Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
about
Improving outcomes of refractory celiac disease - current and emerging treatment strategiesAdvances in the development of new biologics in inflammatory bowel diseaseTargeted therapeutics in SLE: emerging strategies to modulate the interferon pathwaySelective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumabTargeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular diseaseIntegrating Immunologic Signaling Networks: The JAK/STAT Pathway in Colitis and Colitis-Associated CancerType I/II cytokines, JAKs, and new strategies for treating autoimmune diseasesPromising biological therapies for ulcerative colitis: A review of the literatureFuture perspectives in target-specific immunotherapies of myasthenia gravisCurrent stage in inflammatory bowel disease: What is next?Medical Therapy of Active Ulcerative ColitisDecoding the non-coding genome: elucidating genetic risk outside the coding genomeManagement of ulcerative colitisAdvances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel diseaseThe regulation of inflammation by interferons and their STATsRisk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase InhibitorsGenetic update on inflammatory factors in ulcerative colitis: Review of the current literatureClassical and recent advances in the treatment of inflammatory bowel diseasesJanus kinase inhibitors in autoimmune diseasesSTAT3 and sphingosine-1-phosphate in inflammation-associated colorectal cancerJakpot! New small molecules in autoimmune and inflammatory diseasesInflammatory pathways of importance for management of inflammatory bowel diseasePathogenesis of primary sclerosing cholangitis and advances in diagnosis and managementIn vivo administration of a JAK3 inhibitor during acute SIV infection leads to significant increases in viral load during chronic infectionRac Attack: Modulation of the Small GTPase Rac in Inflammatory Bowel Disease and Thiopurine TherapyNext-Generation Therapeutics for IBDKinase-Independent Small-Molecule Inhibition of JAK-STAT SignalingCurrent, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosisCurrent approaches to the management of new-onset ulcerative colitis.Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease.Application of Physiologically-Based Pharmacokinetic Modeling for the Prediction of Tofacitinib Exposure in JapaneseStat3 activation in murine colitis induced by enterotoxigenic Bacteroides fragilis.Update on Janus kinase antagonists in inflammatory bowel disease.Back to the future: oral targeted therapy for RA and other autoimmune diseases.What's fueling the biotech engine-2011 to 2012.An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders.In search of magic bullets: the golden age of immunotherapeutics.
P2860
Q26740769-123019E6-0A8A-4D9A-A100-B35FFBB1F025Q26745782-CE0DCFD9-1E34-4BAB-9C60-2C2D967CBEB9Q26746697-1CB75F7D-7AC6-4DA2-9E25-5A5A1D64947BQ26750456-86F27CB6-A917-4CAC-ADE0-7255E9512331Q26750725-AE8EA91D-7F1A-471C-8309-80EBBA83498FQ26764757-0F70284F-ECAC-45D7-BF84-00346004D92AQ26775111-AF53DBD2-3685-432C-BF25-C48BEA941DF4Q26776139-EDB6C24E-4780-4291-8CAF-1DBB0DCE4C15Q26776225-9EEEBCCC-A42C-40F8-B3CC-9ED895750516Q26777429-BEC53B49-8979-458D-9CA5-7747C0C62BC8Q26777729-1444B66C-C9D3-4956-B187-14B3DF1F8DC3Q26777924-F18215EC-BCCA-40DA-A61E-E6BCBE2DD1FBQ26778250-7B5B58B3-13D5-4895-A92E-26DC74428D8EQ26798299-72292ABD-E8AA-48CF-9905-2F24CB0196B8Q26822029-776A2797-50E6-402A-9EA8-1D8FFF51287FQ26829387-2BFC7D0E-084B-467D-B841-A67008CD3F81Q26851417-A8A8DC33-EF53-4BE0-926A-7A52116E5D13Q26852514-4C152532-6C4B-489A-BA5E-2BB67A8B13CDQ26861725-B4B93E62-E169-4CF4-82BE-E9994608C05BQ26865446-14114034-D0FC-47E0-AD0D-5DF347BE99D7Q26998940-AF9DBF6E-AB48-44A4-97F1-469E00851201Q27001957-A31C06E4-23DA-4F19-A6A2-55560589F6CCQ27005445-C6BBEBD3-C385-4879-89E6-D2A825CBA295Q27015831-763BA87F-C407-4691-9A8E-286E7B9D866BQ27330386-DA4D1DA3-01DD-480E-A76A-9990E3E45976Q28067937-94240F07-A67C-47C1-A0E8-C8984B9BEC66Q28082306-6BF004D9-3A0C-4201-B74E-7EE2F2D99FC7Q28828592-5A615FDC-E23E-4CC9-96E6-CC2DF6E49C89Q30902172-230F2297-5E65-4D52-BF74-9F26C25FE660Q33429617-30A50B10-4037-4269-BB91-20D1F8D3E607Q33633288-90008424-9DED-4A22-8361-95DB6C895B5EQ33654733-72BD34B3-C2A3-4325-9287-BB8DBEB27F2AQ33703161-A9310364-004F-4BDA-A451-060E7365991EQ34002679-6B868A2F-D60D-46FE-A0F0-92224119B1D6Q34030650-22CE9CF3-386D-478B-8195-FC1539F5C2F5Q34213332-77C398B4-3EC0-4CD6-B2E4-A19442AA93E9Q34316400-D6A3229C-F28A-4791-81F9-7D06701AF2A0Q34343220-A9EE5446-AE1B-497B-A6B3-BEE7DAC786CCQ34349150-A38B9DD1-A5A0-4311-807A-AC762CE4E6BCQ34356481-83386638-5B5B-4AE2-B822-3011C8DDD1C4
P2860
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
@en
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
@nl
type
label
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
@en
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
@nl
prefLabel
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
@en
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
@nl
P2093
P356
P1476
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
@en
P2093
Ivana Vranic
Samantha Rousell
Study A3921063 Investigators
Subrata Ghosh
Wojciech Niezychowski
P304
P356
10.1056/NEJMOA1112168
P407
P577
2012-08-01T00:00:00Z